REVIEW
Is cellular senescence an example of antagonistic pleiotropy?
Stefano Giaimo,
Fabrizio d’Adda di Fagagna,
Stefano Giaimo
IFOM Foundation – The FIRC Institute of Molecular Oncology Foundation via Adamello 16, 20139 Milan, Italy
SEMM – European School of Molecular Medicine via Adamello 16, 20139 Milan, Italy
Search for more papers by this authorFabrizio d’Adda di Fagagna
IFOM Foundation – The FIRC Institute of Molecular Oncology Foundation via Adamello 16, 20139 Milan, Italy
Istituto di Genetica Molecolare-Consiglio Nazionale delle Ricerche, Via Abbiategrasso 207, 27100 Pavia, Italy
Search for more papers by this authorStefano Giaimo,
Fabrizio d’Adda di Fagagna,
Stefano Giaimo
IFOM Foundation – The FIRC Institute of Molecular Oncology Foundation via Adamello 16, 20139 Milan, Italy
SEMM – European School of Molecular Medicine via Adamello 16, 20139 Milan, Italy
Search for more papers by this authorFabrizio d’Adda di Fagagna
IFOM Foundation – The FIRC Institute of Molecular Oncology Foundation via Adamello 16, 20139 Milan, Italy
Istituto di Genetica Molecolare-Consiglio Nazionale delle Ricerche, Via Abbiategrasso 207, 27100 Pavia, Italy
Search for more papers by this authorFabrizio d’Adda di Fagagna, IFOM Foundation – The FIRC Institute of Molecular Oncology Foundation, via Adamello 16, 20139 Milan, Italy. Tel. +39 02 574303 227; fax +39 02 574303 231; e-mail: [email protected]
Summary
It is generally accepted that the permanent arrest of cell division known as cellular senescence contributes to aging by an antagonistic pleiotropy mechanism: cellular senescence would act beneficially early in life by suppressing cancer, but detrimentally later on by causing frailty and, paradoxically, cancer. In this review, we show that there is room to rethink this common view. We propose a critical appraisal of the arguments commonly brought in support of it, and we qualitatively analyse published results that are of relevance to understand whether or not cellular senescence-associated genes really act in an antagonistic-pleiotropic manner in humans.
References
- Acosta J. C., O’Loghlen A., Banito A., Guijarro M. V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., Takatsu Y., Melamed J., d’Adda di Fagagna F., Bernard D., Hernando E., Gil Js. (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018.
- Adams P. D. (2009) Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol. Cell 36, 2–14.
- d’Adda di Fagagna F. (2008) Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8, 512–522.
- d’Adda di Fagagna F., Reaper P. M., Clay-Farrace L., Fiegler H., Carr P., von Zglinicki T., Saretzki G., Carter N. P., Jackson S. P. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198.
- Ancrile B., Lim K.-H., Counter C. M. (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21, 1714–1719.
- Ara S., Lee P. S., Hansen M. F., Saya H. (1990) Codon 72 polymorphism of the TP53 gene. Nucleic. Acids Res. 18, 4961.
- Baker D. J., Wijshake T., Tchkonia T., LeBrasseur N. K., Childs B. G., van de Sluis B., Kirkland J. L., van Deursen J. M. (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232–236.
- Bartholomew J. N., Volonte D., Galbiati F. (2009) Caveolin-1 regulates the antagonistic pleiotropic properties of cellular senescence through a Novel Mdm2/p53-mediated pathway. Cancer Res. 69, 2878–2886.
- Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.-V. F., Kolettas E., Niforou K., Zoumpourlis V. C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C. L., Dyrskjot L., Orntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T. D., Bartek J., Gorgoulis V. G. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637.
- Beckman G., Birgander R., Själander A., Saha N., Holmberg P. A., Kivela A., Beckman L. (1994) Is p53 polymorphism maintained by natural selection? Hum. Hered. 44, 266–270.
- Bereir R. E. H., Mohamed H. S., Seielstad M., El Hassan A. M., Khalil E. A. G., Peacock C. S., Blackwell J. M., Ibrahim M. E. (2003) Allele frequency and genotype distribution of polymorphisms within disease-related genes is influenced by ethnic population sub-structuring in Sudan. Genetica 119, 57–63.
- Bergamaschi D., Samuels Y., Sullivan A., Zvelebil M., Breyssens H., Bisso A., Del Sal G., Syed N., Smith P., Gasco M., Crook T., Lu X. (2006) iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat. Genet. 38, 1133–1141.
- Blagosklonny M. V. (2010) Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle 9, 3151–3156.
- Bonafè M., Olivieri F., Mari D., Baggio G., Mattace R., Berardelli M., Sansoni P., De Benedictis G., De Luca M., Marchegiani F., Cavallone L., Cardelli M., Giovagnetti S., Ferrucci L., Amadio L., Lisa R., Tucci M. G., Troiano L., Pini G., Gueresi P., Morellini M., Sorbi S., Passeri G., Barbi C., Valensin S., Monti D., Deiana L., Pes G. M., Carru C., Franceschi C. (1999) p53 Codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am. J. Hum. Genet. 65, 1782–1785.
- Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A. H. F. M., Schlegelberger B., Stein H., Dorken B., Jenuwein T., Schmitt C. A. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665.
- Campisi J. (2001) Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11, S27–S31.
- Campisi J. (2003) Cancer and ageing: rival demons? Nat. Rev. Cancer 3, 339–349.
- Campisi J. (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513–522.
- Campisi J. (2011) Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 21, 107–112.
- Campisi J., d’Adda di Fagagna F. (2007) Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729–740.
-
Charlesworth B. (1994). Evolution in Age-Structured Populations. Cambridge: Cambridge University Press.
10.1017/CBO9780511525711 Google Scholar
- Charlesworth B. (1996) Evolution of senescence: Alzheimer’s disease and evolution. Curr. Biol. 6, 20–22.
- Chen Z., Trotman L. C., Shaffer D., Lin H.-K., Dotan Z. A., Niki M., Koutcher J. A., Scher H. I., Ludwig T., Gerald W., Cordon-Cardo C., Paolo Pandolfi P. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730.
- Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A. J., Barradas M., Benguria A., Zaballos A., Flores J. M., Barbacid M., Beach D., Serrano M. (2005) Tumour biology: senescence in premalignant tumours. Nature 436, 642.
- Coppé J.-P., Patil C. K., Rodier F., Sun Y., Muñoz D. P., Goldstein J., Nelson P. S., Desprez P.-Y., Campisi J. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of Oncogenic RAS and the p53 Tumor Suppressor. PLoS Biol. 6, e301.
- Coulam C. B., Kay C., Jeyendran R. S. (2006) Role of p53 codon 72 polymorphism in recurrent pregnancy loss. RBM Online. 12, 378–382.
- Curtsinger J., Service P., Prout T. (1994) Antagonistic pleiotropy, reversal of dominance, and genetic polymorphism. Am. Nat. 144, 210–228.
- Dato S., Carotenuto L., De Benedictis G. (2007) Genes and longevity: a genetic-demographic approach reveals sex- and age-specific gene effects not shown by the case–control approach (APOE and HSP70.1 loci). Biogerontology 8, 31–41.
- Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre M., Giovanni Nuciforo P., Bensimon A., Maestro R., Giuseppe Pelicci P., d’Adda di Fagagna F. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638–642.
- Dimri G. P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E. E., Linskens M., Rubelj I., Pereira-Smith O. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367.
- Dumont P., Leu J. I. J., Della Pietra A. C., George D. L., Murphy M. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357–365.
- Flatt T., Promislow D. E. L. (2007) Still pondering an age-old question. Science 318, 1255–1256.
- Fossel M. (2003) The Progerias. J Anti-Aging Med. 6, 123–138.
- García-Cao I., García-Cao M., Martín-Caballero J., Criado L. M., Klatt P., Flores J. M., Weill J.-C., Blasco M. A., Serrano M. (2002) “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225–6235.
- Halazonetis T. D., Gorgoulis V. G., Bartek J. (2008) An oncogene-induced DNA damage model for cancer development. Science 319, 1352–1355.
- Harley C. B., Futcher A. B., Greider C. W. (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460.
- Harris S. L., Levine A. J. (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899–2908.
- Hasty P., Campisi J., Hoeijmakers J., van Steeg H., Vijg J. (2003) Aging and genome maintenance: lessons from the mouse? Science 299, 1355–1359.
- Hayflick L. (1965) The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636.
- Hayflick L., Moorhead P. S. (1961) The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621.
- van Heemst D., Mooijaart S. P., Beekman M., Schreuder J., de Craen A. J. M., Brandt B. W., Eline Slagboom P., Westendorp R. G. J., on behalf of the Long Life’ study group (2005) Variation in the human TP53 gene affects old age survival and cancer mortality. Exp. Gerontol. 40, 11–15.
- Helland A., Langerod A., Johnsen H., Olsen A. O., Skovlund E., Borresen-Dale A.-L. (1998) p53 polymorphism and risk of cervical cancer. Nature 396, 530–531.
- Herbig U., Jobling W. A., Chen B. P. C., Chen D. J., Sedivy J. M. (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but Not p16INK4a. Mol. Cell 14, 501–513.
- Hildesheim A., Schiffman M., Brinton L. A., Fraumeni J. F., Herrero R., Bratti M. C., Schwartz P., Mortel R., Barnes W., Greenberg M., McGowan L., Scott D. R., Martin M., Herrera J. E., Carrington M. (1998) p53 polymorphism and risk of cervical cancer. Nature 396, 531–532.
- Hirsch H. R. (1995) Do intersections of mortality-rate and survival functions have significance? Exp. Gerontol. 30, 147–167.
- Jackson S. P., Bartek J. (2009) The DNA-damage response in human biology and disease. Nature 461, 1071–1078.
- Jeyapalan J. C., Ferreira M., Sedivy J. M., Herbig U. (2007) Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev. 128, 36–44.
- Jun J.-I., Lau L. F. (2010) The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 12, 676–685.
- Kang H.-J., Feng Z., Sun Y., Atwal G., Murphy M. E., Rebbeck T. R., Rosenwaks Z., Levine A. J., Hu W. (2009) Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc. Natl Acad. Sci. USA. 106, 9761–9766.
- Kang T.-W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., Hohmeyer A., Gereke M., Rudalska R., Potapova A., Iken M., Vucur M., Weiss S., Heikenwalder M., Khan S., Gil J., Bruder D., Manns M., Schirmacher P., Tacke F., Ott M., Luedde T., Longerich T., Kubicka S., Zender L. (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547–551.
- Kirkwood T. B. L. (2002) p53 and ageing: too much of a good thing? BioEssays 24, 577–579.
- Kirkwood T. B. L. (2005) Understanding the odd science of aging. Cell 120, 437–447.
- Krizhanovsky V., Yon M., Dickins R. A., Hearn S., Simon J., Miething C., Yee H., Zender L., Lowe S. (2008) Senescence of activated stellate cells limits liver fibrosis. Cell 135, 657–668.
- Krtolica A., Parrinello S., Lockett S., Desprez P.-Y., Campisi J. (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA. 98, 12072–12077.
- Kuilman T., Peeper D. S. (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9, 81–94.
- Kuilman T., Michaloglou C., Vredeveld L. C. W., Douma S., van Doorn R., Desmet C. J., Aarden L. A., Mooi W. J., Peeper D. S. (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031.
- Leroi A. M., Bartke A., Benedictis G. D., Franceschi C., Gartner A., Gonos E., Feder M. E., Kivisild T., Lee S., Kartal-Özer N., Schumacher M., Sikora E., Slagboom E., Tatar M., Yashin A. I., Vijg J., Zwaan B. (2005) What evidence is there for the existence of individual genes with antagonistic pleiotropic effects? Mech. Ageing Dev. 126, 421–429.
- Lewis S. J., Brunner E. J. (2004) Methodological problems in genetic association studies of longevity‘Äîthe apolipoprotein E gene as an example. Int. J. Epidemiol. 33, 962–970.
- Maynard Smith J. (1962) Review lectures on senescence. I. The causes of ageing. Proc Royal Soc Lond., B, Biol. Sci. 157, 115–127.
- Medawar P. B. (1946) Old age and natural death. Mod. Quarterly. 1, 30–56.
- Medawar P. B. (1952). An Unsolved Problem of Biology. London: H.K. Lewis and Co.
- Mendrysa S. M., O’Leary K. A., McElwee M. K., Michalowski J., Eisenman R. N., Powell D. A., Perry M. E. (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20, 16–21.
- Michaloglou C., Vredeveld L. C. W., Soengas M. S., Denoyelle C., Kuilman T., van der Horst C. M. A. M., Majoor D. M., Shay J. W., Mooi W. J., Peeper D. S. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724.
- Moorad J. A., Promislow D. E. L. (2009) What can genetic variation tell us about the evolution of senescence? Proc. Royal Soc., B, Biol. Sci. 276, 2271–2278.
- Ørsted D. D., Bojesen S. E., Tybjaerg-Hansen A., Nordestgaard B. G. (2007) Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J. Exp. Med. 204, 1295–1301.
- Partridge L., Gems D. (2006) Beyond the evolutionary theory of ageing, from functional genomics to evo-gero. Trends Ecol. Evol. 21, 334–340.
- Pelicci P. G. (2004) Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? J. Clin. Investig. 113, 4–7.
- Pim D., Banks L. (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 108, 196–199.
- Puente X., Velasco G., Gutierrez-Fernandez A., Bertranpetit J., King M.-C., Lopez-Otin C. (2006) Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics. 7, 1–9.
- den Reijer P. M., Maier A. B., Westendorp R. G. J., van Heemst D. (2008) Influence of the TP53 codon 72 polymorphism on the cellular responses to X-irradiation in fibroblasts from nonagenarians. Mech. Ageing Dev. 129, 175–182.
- Rodier F., Campisi J. (2011) Four faces of cellular senescence. J. Cell Biol. 192, 547–556.
- Rose M. R. (1982) Antagonistic pleiotropy, dominance, and genetic variation. Heredity 48, 63–78.
- Rose M., Charlesworth B. (1980) A test of evolutionary theories of senescence. Nature 287, 141–142.
- Salvioli S., Bonafé M., Barbi C., Storci G., Trapassi C., Tocco F., Gravina S., Rossi M., Tiberi L., Mondello C., Monti D., Franceschi C. (2005) p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle (Georgetown, Tex.). 4, 1264–1271.
- Schächter F., Faure-Delanef L., Guenot F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen D. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 6, 29–32.
- Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. (1997) Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a. Cell 88, 593–602.
- Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I. M., Matlashewski G., Banks L. (1998) Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 393, 229–234.
- Tatar M., Kopelman A., Epstein D., Tu M.-P., Yin C.-M., Garofalo R. S. (2001) A mutant drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 292, 107–110.
- Toupance B., Godelle B., Gouyon P.-H., Schächter F. (1998) A model for antagonistic pleiotropic gene action for mortality and advanced age. Am J Hum Genet. 62, 1525–1534.
- Tyner S. D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., Lu X., Soron G., Cooper B., Brayton C., Hee Park S., Thompson T., Karsenty G., Bradley A., Donehower L. A. (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45–53.
-
Weismann A. (1889). Essays Upon Heredity and Kindred Biological Problems. Oxford: Clarendon press.
10.5962/bhl.title.101564 Google Scholar
- Whibley C., Pharoah P. D. P., Hollstein M. (2009) p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95–107.
- Williams G. C. (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution 11, 398–411.
- Wilson R. H., Morgan T. J., Mackay T. F. C. (2006) High-resolution mapping of quantitative trait loci affecting increased life span in drosophila melanogaster. Genetics 173, 1455–1463.
- Wright W. E., Shay J. W. (1995) Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol. 5, 293–297.
- Wright W. E., Shay J. W. (2001) Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev. 11, 98–103.
- Xue W., Zender L., Miething C., Dickins R. A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S. W. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660.
- Zehbe I., Voglino G., Wilander E., Genta F., Tommasino M. (1999) Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354, 218–219.
- Zwaan B. J. (2003) Linking development and aging. Sci. Aging Knowl. Environ. 47, pe32.
